Is Peptide Therapy Right for You? How a Medical Care Provider Actually Evaluates It
The question isn’t whether peptides work. For many people, in the right context, they do. The question is whether they’re right for you — and answering that requires more than a protocol borrowed from someone online.
The First Thing We Look At: Your Overall Health Picture
The first place any good evaluation starts is your overall health picture. Not in a checklist way, but genuinely. Are there underlying conditions that aren’t as well-controlled as you’d like? Arthritis that’s mostly managed but still flares. Lingering discomfort from an old injury. Skin and hair changes you’ve noticed but haven’t addressed. A lot of people don’t volunteer this right away because they don’t connect it to what they’re asking about. But those details often point directly toward which peptides could be relevant — and which should be approached carefully or avoided altogether.
Then We Talk About Your Goals
If nothing significant surfaces there, the conversation moves to goals. What do you want your body to do that it isn’t doing right now? This isn’t about optimization culture. It’s about identifying a specific, addressable gap. Slow recovery from exercise. Body composition that isn’t responding to effort. Sleep quality that has slipped. These are real, measurable things. If a peptide can help address them and the risk profile supports it, there’s a basis for a protocol.
If You’re Already on a GLP-1, the Conversation Gets More Specific
For patients already on a GLP-1, the conversation often takes a particular shape — and it’s one the Ivim clinical team has frequently. GLP-1 treatment is highly effective, but it creates downstream considerations that a lot of patients don’t anticipate. Body composition shifts. Lean muscle mass can decline if it isn’t actively supported. Recovery capacity changes. Skin changes. These aren’t reasons to avoid GLP-1 therapy — they’re reasons to think carefully about what else your body may need alongside it.
Different peptides tend to be most relevant at different stages of GLP-1 treatment, and timing matters. As Dr. Duncan notes, someone three months into treatment has different needs than someone who has been on it for a year and is thinking about what maintenance looks like. That’s a conversation worth having early, not after the fact.
What Good Medical Oversight Actually Means
What a thorough evaluation isn’t doing is looking for a reason to prescribe. Peptides carry risk. The benefit genuinely has to outweigh the risk — and a provider needs to be able to make that case for each patient based on their actual picture. If it doesn’t add up, the answer is no. As Dr. Duncan puts it: “That’s what medical oversight means in practice. Not gatekeeping. An honest evaluation of what’s likely to help, and the willingness to say when the answer is not this.”
Why the Ivim Model Makes a Difference Here
This kind of evaluation isn’t a one-time conversation. At Ivim, our clinical team is available for unlimited consultations — because your needs at the start of a protocol and six months in are rarely the same. We work with patients across 49 states, and our providers stay involved as your protocol evolves. If something isn’t working, we adjust. If your goals change, we reassess. That ongoing relationship is what makes the difference between a protocol that’s prescribed and a protocol that actually works.
Frequently Asked Questions
What should I bring to my first consultation about peptides?
A list of your current medications, any relevant health history — injuries, chronic conditions, surgeries — and a clear sense of what you’re hoping to address. You don’t need to arrive having decided what you want. That’s what the evaluation is for. But the more specific you can be about what isn’t working the way you’d like, the more useful the conversation will be.
What disqualifies someone from peptide therapy?
Disqualifying factors vary by compound. Certain medical conditions, drug interactions, or health histories can shift the risk-benefit calculation in a direction that makes a given peptide inappropriate. A history of certain cancers, for example, may be relevant to peptides that affect growth hormone. A medical care provider who knows your full history is positioned to make that call accurately.
Can I ask about peptides during a GLP-1 consultation?
Yes, and we’d encourage it. Many Ivim patients begin asking about peptides in the context of their GLP-1 treatment, often because they’re noticing specific changes — in recovery, body composition, or skin — that they want to address. That’s a natural entry point for the conversation, and our clinical team is equipped to discuss both.
How long does a peptide evaluation take?
The clinical evaluation is part of a consultation with your medical care provider. What matters more than the duration is the depth — a good evaluation covers your health history, your wellness goals, and the specific risk-benefit picture for any peptide being considered. At Ivim, that conversation doesn’t have a time limit.
